Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The Safety and Immunogenicity of Rotavirus Vaccination in Infants With Intestinal Failure.

Javid PJ, Sanchez SE, Jacob S, McNeal MM, Horslen SP, Englund JA.

J Pediatric Infect Dis Soc. 2014 Mar;3(1):57-65. doi: 10.1093/jpids/pit060. Epub 2013 Oct 14.

2.

A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.

Dang DA, Nguyen VT, Vu DT, Nguyen TH, Nguyen DM, Yuhuan W, Baoming J, Nguyen DH, Le TL; Rotavin-M1 Vaccine Trial Group.

Vaccine. 2012 Apr 27;30 Suppl 1:A114-21. doi: 10.1016/j.vaccine.2011.07.118.

PMID:
22520120
3.

Safety and immunogenicity of tetravalent rhesus-based rotavirus vaccine in Bangladesh.

Bresee JS, El Arifeen S, Azim T, Chakraborty J, Mounts AW, Podder G, Gentsch JR, Ward RL, Black R, Glass RI, Yunus M.

Pediatr Infect Dis J. 2001 Dec;20(12):1136-43.

PMID:
11740320
4.

Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.

Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH, De Vos B, Bock HL.

J Infect Dis. 2005 Sep 1;192 Suppl 1:S6-S16.

PMID:
16088807
5.

Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants.

Dhingra MS, Kundu R, Gupta M, Kanungo S, Ganguly N, Singh MP, Bhattacharya MK, Ghosh R, Kumar R, Sur D, Chadha SM, Saluja T.

Vaccine. 2014 Aug 11;32 Suppl 1:A117-23. doi: 10.1016/j.vaccine.2014.03.069.

6.

Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial.

Lau YL, Nelson EA, Poon KH, Chan PK, Chiu S, Sung R, Leung CW, Ng D, Ma YM, Chan D, Lee TL, Tang J, Kwan YW, Ip P, Ho M, Fung LW, Tang H, Suryakiran PV, Han HH, Bock H; Hong Kong Rotarix Study Group.

Vaccine. 2013 Apr 26;31(18):2253-9. doi: 10.1016/j.vaccine.2013.03.001. Epub 2013 Mar 13.

7.

Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.

Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, Smolenov IV, Han HH; ROTA-054 Study Group.

Pediatr Infect Dis J. 2012 May;31(5):487-93. doi: 10.1097/INF.0b013e3182490a2c.

PMID:
22228231
8.

Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants.

Vesikari T, Prymula R, Schuster V, Tejedor JC, Cohen R, Bouckenooghe A, Damaso S, Han HH.

Pediatr Infect Dis J. 2012 May;31(5):509-13. doi: 10.1097/INF.0b013e3182489cac.

PMID:
22228235
9.

Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine.

Dennehy PH, Brady RC, Halperin SA, Ward RL, Alvey JC, Fischer FH Jr, Innis BL, Rathfon H, Schuind A, De Vos B; North American Human Rotavirus Vaccine Study Group.

Pediatr Infect Dis J. 2005 Jun;24(6):481-8.

PMID:
15933555
10.

An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone?

Haber P, Chen RT, Zanardi LR, Mootrey GT, English R, Braun MM; VAERS Working Group.

Pediatrics. 2004 Apr;113(4):e353-9.

PMID:
15060267
11.

Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation.

Clark HF, Burke CJ, Volkin DB, Offit P, Ward RL, Bresee JS, Dennehy P, Gooch WM, Malacaman E, Matson D, Walter E, Watson B, Krah DL, Dallas MJ, Schödel F, Kaplan kM, Heaton P.

Pediatr Infect Dis J. 2003 Oct;22(10):914-20.

PMID:
14551493
12.

Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan.

Chang CC, Chang MH, Lin TY, Lee HC, Hsieh WS, Lee PI.

J Formos Med Assoc. 2009 Apr;108(4):280-5. doi: 10.1016/S0929-6646(09)60067-X.

14.

Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine. US Rhesus Rotavirus Vaccine Study Group.

Dennehy PH, Rodgers GC Jr, Ward RL, Markwick AJ, Mack M, Zito ET.

Pediatr Infect Dis J. 1996 Nov;15(11):1012-8.

PMID:
8933551
15.

Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants.

Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq E, Forster J, Zepp F, Delem A, De Vos B.

Vaccine. 2004 Jul 29;22(21-22):2836-42.

PMID:
15246619
16.

Reactogenicity and immunogenicity of a high-titer rhesus rotavirus-based quadrivalent rotavirus vaccine.

Flores J, Perez-Schael I, Blanco M, Rojas AM, Alfonzo E, Crespo I, Cunto W, Pittman AL, Kapikian AZ.

J Clin Microbiol. 1993 Sep;31(9):2439-45.

17.

Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.

Danchin M, Kirkwood CD, Lee KJ, Bishop RF, Watts E, Justice FA, Clifford V, Cowley D, Buttery JP, Bines JE.

Vaccine. 2013 May 28;31(23):2610-6. doi: 10.1016/j.vaccine.2013.04.008. Epub 2013 Apr 16.

PMID:
23597719
18.

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.

Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM; Pentavalent Rotavirus Vaccine Dose Confirmation Efficacy Study Group.

Pediatrics. 2007 Jan;119(1):11-8.

PMID:
17200266
19.

Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.

Bines JE, Danchin M, Jackson P, Handley A, Watts E, Lee KJ, West A, Cowley D, Chen MY, Barnes GL, Justice F, Buttery JP, Carlin JB, Bishop RF, Taylor B, Kirkwood CD; RV3 Rotavirus Vaccine Program.

Lancet Infect Dis. 2015 Dec;15(12):1389-97. doi: 10.1016/S1473-3099(15)00227-3. Epub 2015 Aug 26.

PMID:
26318715
20.

Rotavirus vaccines and vaccination in Latin America.

Linhares AC, Bresee JS.

Rev Panam Salud Publica. 2000 Nov;8(5):305-31. Review.

PMID:
11190969

Supplemental Content

Support Center